---
title: "inflammatory myopathies"
slug: "inflammatory-myopathies"
date: "2023-08-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[connective tissue diseases]]

# inflammatory myopathies

- [[Definition and epidemiology of inflammatory myopathies|Definition and epidemiology]] ó°’– (NEJM 2015;372:1734; Lancet Neurol 2018;17:816)
- [[Clinical manifestations of inflammatory myopathies|Clinical manifestations]] ó°’–
- Diagnostic studies (Ann Rheum Dis 2017;76:1955)
  - â†‘ CK (rarely >100,000 U/L, can be â†‘â†‘â†‘ in NM), aldolase, SGOT, LDH; Â± â†‘ ESR & CRP
    - [[Autoantibodies of inflammatory myopathies|Autoantibodies]] ó°’–: âŠ• ANA (>75%)
    - Consider EMG (â†‘ spontaneous activity, â†“ amplitude, polyphasic potentials w/ contraction) or MRI (muscle edema, inflammation, atrophy) for evaluation; may guide biopsy
    - [[Pathology and muscle biopsy of inflammatory myopathies|Pathology and muscle biopsy]] ó°’–

## Treatment (Nat Rev Rheum 2018;14:279)

- Immunosuppression not effective for IBM. For all others:
- Steroids (prednisone 1 mg/kg); MTX or AZA early if mod/severe or taper fails (2-3 mo)
- For resistant (30-40%) or severe disease: AZA/MTX combo, IVIg (NM, DM Â± PM), rituximab, MMF, cyclophosphamide (esp. if ILD or vasculitis)
- IVIg w/ pulse steroids acutely for life-threatening esophageal or resp muscle involvement
- âœ“ for occult malignancy (esp. if DM); monitor respiratory muscle strength with spirometry
- NM: stop statin; steroids + MTX, RTX, or IVIg
